Advertisement
U.S. Markets close in 3 hrs 36 mins

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - Nasdaq Real Time Price. Currency in USD
Visitors trend2W10W9M
18.25+0.07 (+0.36%)
As of 12:24PM EDT. Market open.
Advertisement
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
16,289,000
15,845,000
14,925,000
15,879,000
16,658,000
-
Cost of Revenue
8,227,000
8,200,000
7,952,000
8,284,000
8,933,000
-
Gross Profit
8,062,000
7,645,000
6,973,000
7,594,000
7,726,000
-
Operating Expense
4,564,000
4,451,000
4,283,000
4,495,000
4,668,000
-
Operating Income
3,498,000
3,194,000
2,690,000
3,099,000
3,058,000
-
Net Non Operating Interest Income Expense
-1,058,000
-1,095,000
-991,000
-962,000
-963,000
-
Other Income Expense
-2,583,000
-2,723,000
-4,859,000
-1,480,000
-6,500,000
-
Pretax Income
-142,000
-624,000
-3,163,000
658,000
-4,406,000
-
Tax Provision
606,000
-7,000
-643,000
211,000
-168,000
-
Earnings from Equity Interest Net of Tax
-1,000
2,000
21,000
9,000
138,000
-
Net Income Common Stockholders
-453,000
-559,000
-2,446,000
417,000
-3,990,000
-
Diluted NI Available to Com Stockholders
-453,000
-559,000
-2,446,000
417,000
-3,990,000
-
Basic EPS
-1.98
-0.50
-2.12
0.38
-3.64
-
Diluted EPS
-1.98
-0.50
-2.12
0.38
-3.64
-
Basic Average Shares
1,117,500
1,119,000
1,110,000
1,102,000
1,095,000
-
Diluted Average Shares
1,117,500
1,119,000
1,110,000
1,107,000
1,095,000
-
Total Operating Income as Reported
877,000
433,000
-2,197,000
1,716,000
-3,572,000
-
Total Expenses
12,791,000
12,651,000
12,235,000
12,779,000
13,601,000
-
Net Income from Continuing & Discontinued Operation
-453,000
-559,000
-2,446,000
417,000
-3,990,000
-
Normalized Income
1,527,440
2,122,910
1,420,400
1,409,503
1,427,664
-
Interest Expense
992,000
1,029,000
930,000
891,000
901,000
-
Net Interest Income
-1,058,000
-1,095,000
-991,000
-962,000
-963,000
-
EBIT
850,000
405,000
-2,233,000
1,549,000
-3,505,000
-
EBITDA
1,930,000
1,558,000
-925,000
2,879,000
-1,948,000
-
Reconciled Cost of Revenue
8,227,000
8,200,000
7,952,000
8,284,000
8,933,000
-
Reconciled Depreciation
1,080,000
1,153,000
1,308,000
1,330,000
1,557,000
-
Net Income from Continuing Operation Net Minority Interest
-453,000
-559,000
-2,446,000
417,000
-3,990,000
-
Total Unusual Items Excluding Goodwill
-2,572,000
-2,709,000
-4,833,000
-1,461,000
-6,496,000
-
Total Unusual Items
-2,572,000
-2,709,000
-4,833,000
-1,461,000
-6,496,000
-
Normalized EBITDA
4,502,000
4,267,000
3,908,000
4,340,000
4,548,000
-
Tax Rate for Calcs
0
0
0
0
0
-
Tax Effect of Unusual Items
-591,560
-27,090
-966,600
-468,497
-1,078,336
-